general/pan tumour

Edit Answers
12345678910111213141516171819
Across
  1. 2. Criteria used to select patients for clinical trials
  2. 6. Profile in which adverse reactions are reported
  3. 10. Number of approved FDA indications for LIBTAYO
  4. 11. Immune function inhibited by LIBTAYO
  5. 13. Statistical method often used in evaluating PFS
  6. 15. Generates fully human therapeutic antibodies, including LIBTAYO
  7. 17. LIBTAYO ________ enhances patient access to LIBTAYO
  8. 19. Information resource that contains efficacy, safety, and usage information for LIBTAYO
Down
  1. 1. 350 mg infusion, every 3 weeks
  2. 3. Color of LIBTAYO
  3. 4. First line immune response
  4. 5. Tumor staging criteria
  5. 7. LIBTAYO biologic
  6. 8. Expresses programmed death-receptor 1 (PD-1)
  7. 9. LIBTAYO biologic
  8. 12. Objective response rate. Duration of Response. Complete response rate. Safety and tolerability.
  9. 14. Administration method of LIBTAYO
  10. 16. Approves drug indications
  11. 18. Method to confirm objective response rate (ORR)